New laboratory tests in acute pancreatitis

Addiction Biology

Volumn 7, Issue 2, 2002, Pages 181-190

  Kylänpää Bäck, Marja Leena ^a,b   Repo, Heikki ^a   Kemppainen, Esko ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; C REACTIVE PROTEIN; TRIACYLGLYCEROL LIPASE; TRYPSINOGEN;

ACUTE PANCREATITIS; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME BLOOD LEVEL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INTENSIVE CARE; LABORATORY TEST; MORTALITY; PANCREAS INSUFFICIENCY; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM;

BIOLOGICAL MARKERS; HUMANS; PANCREATIC FUNCTION TESTS; PANCREATITIS, ACUTE NECROTIZING; PANCREATITIS, ALCOHOLIC; PREDICTIVE VALUE OF TESTS;

EID: 0036255071     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/13556210220120415     Document Type: Review

References (140)

1. Etiopathogenesis of acute pancreatitis
2. Prognostic markers in acute pancreatitis: Can pancreatic necrosis be predicted?
3. Early treatment of acute biliary pancreatitis by endoscopic papillotomy
4. Acute pancreatitis
5. Pancreatitis in Finland between 1970 and 1989
6. Multicentre audit of death from acute pancreatitis
7. An audit of fatal acute pancreatitis
8. A critical review of antibiotic prophylaxis in severe acute pancreatitis
9. Clinical course of acute pancreatitis: What has changed in recent years?
10. Acute pancreatitis: The substantial human and financial cases
11. Which complications of acute pancreatitis are most lethal? A prospective multicentre clinical study of 719 episodes
12. Cytokines as predictors of severity in acute pancreatitis
13. High early mortality rate from acute pancreatitis in Scotland, 1984-1995
14. Multiple organ failure
15. Ingredients of organ dysfunction or failure
16. Sepsis, SIRS, and MODS: What's in a name?
17. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
18. The role of infection in acute pancreatitis
19. Prevention of multiple organ failure
20. Acute pancreatitis: The pathophysiological role of cytokines and integrins
21. Bacterial contamination of pancreatic necrosis
22. Relationship of necrosis to organ failure in severe acute pancreatitis
23. No strict correlation between necrosis and organ failure in acute pancreatitis
24. Prognosis in acute organ-system failure
25. Organ failure and multiple organ system failure in pancreatitis
26. Lipopolysaccharide binding protein in acute pancreatitis
27. Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome
28. Factors influencing morbidity and mortality in acute pancreatitis; an analysis of 279 cases
29. Pulmonary complications in fatal acute hemorrhagic pancreatitis
30. Inflammatory response in the early prediction of severity in human acute pancreatitis
31. Acute pancreatitis: Which patient is most at risk?
32. A prospective audit against management of acute pancreatitis in the south of England
33. Objectification of the severity of acute pancreatitis
34. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation
35. Value of contrast-enhanced computerized tomography in the early diagnosis and prognosis of acute pancreatitis
36. Contrast-enhanced abdominal computed tomography scanning and prediction of severity of acute pancreatitis: A prospective study
37. Patient selection and timing of dynamic computed tomography in acute pancreatitis
38. CT diagnosis and staging of acute pancreatitis
39. Pancreatic imaging
40. Imaging and intervention in acute pancreatitis
41. Value of blood amylase estimations in the diagnosis of pancreatic disease: A clinical study
42. Acute pancreatitis and normoamylasemia. Not an uncommon combination
43. Lipase in serum - The elusive enzyme: An overview
44. Serum enzymes and other laboratory tests in acute pancreatitis
45. Comparison of elastase-1 with amylase, lipase, and trypsin-like immunoreactivity in the diagnosis of acute pancreatitis
46. Amylase, lipase, pancreatic isoamylase, and phospholipase A in diagnosis of acute pancreatitis
47. Serum amylase and lipase in the evaluation of acute abdominal pain
48. What is the best biochemical test to diagnose acute pancreatitis? A prospective clinical study
49. Diagnostic and prognostic utility of phospholipase A activity in patients with acute pancreatitis: Comparison with amylase and lipase
50. A prospective study of serum pancreatic elastase-1 in the diagnosis and assessment of acute pancreatitis
51. Serum lipase determination in acute pancreatitis
52. Assays of serum lipase: Analytical and clinical considerations
53. Screening for acute pancreatitis
54. The clinical chemistry laboratory and acute pancreatitis
55. A comparison of lipase and amylase in the diagnosis of acute pancreatitis in patients with abdominal pain
56. Comparison of serum amylase pancreatic isoamylase and lipase in patients with hyperamylasemia
57. Digestive enzymes and protease inhibitors in plasma from patients with acute pancreatitis
58. Pancreatitis. The role of lysosomes
59. Primary intracellular events in pancreatitis
60. Acute pancreatitis. A review with an emphasis on new developments
61. Plasma immunoreactive anionic pancreatic trypsin in cystic fibrosis
62. Acute pancreatitis. Biochemical, pathophysiological and therapeutic aspects
63. Pathophysiology of acute pancreatitis
64. The early intraacinar cell events which occur during acute pancreatitis
65. Acute necrotizing pancreatitis in the opossum: Earliest morphological changes involve acinar cells
66. Early ducral decompression prevents the progression of biliary panreatitis: An experimental study in the opossum
67. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis
68. Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis
69. Damage prevention versus damage control in acute pancreatitis
70. Ischemia- and reperfusion-related injury in pancreatitis
71. Urine trypsinogen-2 as a marker of acute pancreatitis
72. Immunoreactive anionic and cationic trypsin in human serum
73. Time-resolved immunofluorometric assay of trypsin-2 complexed with alpha 1-antitrypsin in serum
74. Serum complex of trypsin 2 and alpha-1-antitrypsin as diagnostic and prognostic marker of acute pancreatitis: Clinical study in consecutive patients
75. Serum trypsinogen-2 and trypsin-2-alpha1-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas
76. The ratio of trypsin-2-alpha(1)-antitrypsin to trypsinogen-1 discriminates biliary and alcohol-induced acute pancreatitis
77. Urinary trypsinogen-2 test strip for acute pancreatitis
78. Rapid measurement of urinary trypsinogen-2 as a screening test for acute pancreatitis
79. Reliable screening for acute pancreatitis with rapid urine trypsinogen-2 test strip
80. Comparison of urine trypsinogen-2 test strip with serum lipase in the diagnosis of acute pancreatitis
81. Pro- and antiinflammatory cytokines during acute severe pancreatitis: An early and sustained response, although unpredictive of death
82. Controlled trial of urgent endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy versus conservative treatment for acute pancreatitis due to gall stones
83. Biliary pancreatitis needs endoscopic retrograde cholangiopancreatography with endoscopic sphincterotomy for cure
84. Early enteral nutrition in acute pancreatitis
85. Early antibiotic treatment in acute necrotising pancreatitis
86. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem
87. APACHE-II score for assessment and monitoring of acute pancreatitis
88. Pancreatitis inflammatory response syndrome (PIRS)? Can there be another inflammatory response syndrome?
89. Underestimation of acute pancreatitis: Patients with only small increase in amylase/lipase levels can also have or develop severe acute pancreatitis
90. Early detection of acute fulminant pancreatitis by contrast-enhanced computed tomography
91. Prediction of pancreatic necrosis by dynamic pancreatography
92. Acute pancreatitis: Value of CT in establishing prognosis
93. Rapid-bolus contrast-enhanced dynamic computed tomography in acute pancreatitis: A prospective study
94. Prospective comparison of C-reactive protein level, Ranson score and contrast-enhanced computed tomography in the prediction of septic complications of acute pancreatitis
95. Early localization of necrosis by contrast-enhanced computed tomography can predict outcome in severe acute pancreatitis
96. Comparison of MR and CT scanning in severe acute pancreatitis: Initial experiences
97. Contrast-enhanced magnetic resonance imaging for the detection of acute haemorrhagic necrotizing pancreatitis
98. T2-weighted and dynamic enhanced MRI in acute pancreatitis: Comparison with contrast enhanced CT
99. A clinically based classification system for acute pancreatitis. Summary of the international symposium on acute pancreatitis, Atlanta, Georgia, September 11-13, 1992
100. Scoring systems for predicting outcome in acute hemorrhagic necrotizing pancreatitis
101. Prognostic signs and the role of operative management in acute pancreatitis
102. Discriminant power and information content of Ranson's prognostic signs in acute pancreatitis: A meta-analytic study
103. Prediction of outcome in acute pancreatitis: A comparative study of APACHE II, clinical assessment and multiple factor scoring systems
104. Evaluation of prognostic factors in patients with acute pancreatitis
105. Evaluation of severity in patients with acute pancreatitis
106. C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis
107. Relation of alpha2-macroglobulin and other anti-proteases to the clinical features of acute pancreatitis
108. Monitoring of serum proteinase - Antiprotease balance and systemic inflammatory response in prognostic evaluation of acute pancreatitis
109. Alpha2 macroglobulin state in acute pancreatitis. Raised values of alpha2 macroglobulin-protease complexes in severe and mild attacks
110. Trypsinogen activation peptides assay in the early prediction of severity of acute pancreatitis
111. Inflammatory mediators in acute pancreatitis
112. Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: A multicentre study
113. C-reactive protein (CRP) and serum phospholipase A2 in the assessment of the severity of acute pancreatitis
114. Phospholipase A2 in acute pancreatitis: New biochemical and pathological aspects
115. Extracellular phospholipases A2 in relation to systemic inflammatory response syndrome (SIRS) and systemic complications in severe acute pancreatitis
116. Pancreatitis, cytokines, and SIRS: Déjà vu all over again?
117. The role of cytokines in the pathogenesis of acute pancreatitis
118. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma
119. Systemic inflammatory response syndrome
120. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis
121. Procalcitonin, soluble interleukin-2 receptor and soluble E-selectin in predicting the severity of acute pancreatitis
122. Frühe identifizierung der biliären akuten pankreatitis durch procalcitonin-immunireaktivität - Vorläufige ergebnisse
123. Role of procalcitonin and granulocyte colony stimulating factor in the early prediction of infected necrosis in severe acute pancreatitis
124. The strip test of procalcitonin in early detection of severe acute pancreatitis
125. Neutrophil-mediated tissue injury and its modulation
126. Clinical usefulness of polymorphonuclear elastase in predicting the severity of acute pancreatitis: Results of a multicentre study
127. Immune function early in acute pancreatitis
128. Interleukins in acute pancreatitis
129. Blood concentrations of polymorphonuclear leucocyte elastase and inrerleukin-6 are indicators for the occurrence of multiple organ failures at the early stage of acute pancreatitis
130. Rapid elevation of systemic cytokines during acute pancreatitis and their origination within the pancreas
131. Interleukin-6 is a useful marker for early prediction of the severity of acute pancreatitis
132. Cytokine mediators of immunity and inflammation
133. Behavior of serum soluble interleukin-2 receptor, soluble CD8 and soluble CD4 in the early phases of acute pancreatitis
134. Anti-inflammatory cytokines
135. Serum interleukin 10 and interleukin 11 in patients with acute pancreatitis
136. Interleukin 1 receptor antagonist and E-selectin concentrations: A comparison in patients with severe acute pancreatitis and severe sepsis
137. Search for prognostic markers for acute pancreatitis
138. Anti-inflammatory cytokine response and clinical outcome in acute pancreatitis
139. Anti-tumor necrosis factor antibody augments edema formation in caerulein-induced acute pancreatitis
140. Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood